As of Nov 19, 2026, 1 of 1 active firms rate SGMO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SGMO EPS & revenue forecast
EPS · THIS QUARTER
$-0.07
Range $-0.07 – $-0.07 · 1 analysts · -12% YoY
Next period, 1 analysts expect Sangamo Therapeutics Inc to earn $-0.07 a share (range $-0.07 – $-0.07), versus $-0.08 a year earlier. , growing to $-0.03 the year after.
REVENUE · THIS QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Sangamo Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SGMO.
#1
Luca Issi
RBC Capital · Rank #76
Neutral
$2.00+2602.7% to target
Overall win rate
49%
+ Follow
#2
Patrick R. Trucchio
HC Wainwright & Co. · Rank #308
Buy
$10.00+13413.5% to target
Overall win rate
36%
+ Follow
#3
Gena Wang
Barclays · Rank #410
Neutral
$1.00+1251.4% to target
Overall win rate
32%
+ Follow
#4
Ritu Baral
TD Cowen
Buy
No targeton SGMO
Coverage
—
+ Follow
#5
NG
Nicole Germino
Truist Securities
Buy
$5.00+6656.8% to target
Coverage
—
+ Follow
SGMO stock forecast FAQ
What is SGMO's average 12-month price target?+
The 1 active firms with a live target average $10.00 for Sangamo Therapeutics Inc over the next 12 months, ranging from a $10.00 high to a $10.00 low, as of Nov 19, 2026.
Is SGMO stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover SGMO?+
1 active firms have a recognized rating on Sangamo Therapeutics Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SGMO?+
Among analysts who currently cover SGMO, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #76). Their current call is Neutral with a $2.00 target.
What is Sangamo Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.07 per share (range $-0.07 – $-0.07) across 1 analysts. Full-year EPS is projected at —, rising to $-0.03 the following year.
How much revenue is Sangamo Therapeutics Inc expected to report next quarter?+
Consensus revenue is — (range — – —). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading SGMO lately?+
As of Nov 19, 2026, 1 of 1 active firms rate SGMO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SGMO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.